From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Treatment for Tinea Capitis: Griseofulvin or Terbinafine?

A meta-analysis suggests that 4-week courses of terbinafine work as well as 8-week courses of griseofulvin in children with ringworm.

Children who have tinea capitis usually are treated with oral griseofulvin for 6 to 8 weeks. Investigators in Philadelphia conducted a meta-analysis to determine whether short courses of terbinafine yield an equivalent outcome. They reviewed six studies involving 603 children with culture-proven tinea capitis. Children were assigned randomly to either griseofulvin (≥6 weeks) or terbinafine (≥2 weeks).

In an analysis that included all data, no difference was found in the rate of cure at 12 weeks after treatment started. However, one study involved only children in which an uncommon organism, microsporum, was the causative agent. When the remaining five studies (469 children) were analyzed, the cure rate at 12 weeks favored terbinafine, although the difference was not quite significant. The cure rate at 8 weeks (data from four studies) showed virtually no difference.

Comment: Adhering to a 6- to 8-week course of griseofulvin for tinea capitis is quite difficult. Although terbinafine, like many other drugs we use in pediatrics, is not FDA-approved for children, it is growing in popularity. A 4-week course of terbinafine appears to be at least as good as a longer course of griseofulvin.

— Howard Bauchner, MD

Published in Journal Watch General Medicine November 16, 2004

Citation(s):

Fleece D et al. Griseofulvin versus terbinafine in the treatment of tinea capitis: A meta-analysis of randomized, clinical trials. Pediatrics 2004 Nov; 114:1312-5.

Reader Remarks:

Review and add to remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2004. Massachusetts Medical Society. All rights reserved.